Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | FAP | Q12884 | 4/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.32 |
| ▸ | PITRM1 | Q5JRX3 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708511 | 0.79 | BACE1 (0.32) | — | |
| SCHEMBL6559378 | 0.75 | DPP4 (0.37) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL15756820 | 0.73 | DPP4 (0.38) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL7326363 | 0.71 | DPP4 (0.36) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL11204101 | 0.70 | DPP4 (0.35) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL11310350 | 0.70 | DPP4 (0.35) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL7378319 | 0.70 | DPP4 (0.36) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL6338693 | 0.69 | DPP4 (0.35) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL7757818 | 0.69 | DPP4 (0.35) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL10823665 | 0.68 | DPP4 (0.34) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | DPP4 551/4885FAP 1457/4885DPP7 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.